Ulus Ali Şanlı

Prof.Dr.Ulus Ali Şanlı, Türk tıbbi onkologdur.

Akdeniz Üniversitesi Tıp Fakültesi 'nden 1987'de mezun oldu. Ege Üniversitesi Tıp Fakültesi nde iç hastalıkları ve daha sonra da onkoloji uzmanlığı eğitimini tamamladı. Meme kanseri prostat kanseri over kanseri osteosarkom sindirim sistemi kanserleri üzerinde çalıştı. Konusunda birçok uluslararası çalışma ve yayınları bulunmaktadır. Ege Üniversitesi Tıp Fakültesi öğretim üyesidir 2004'te iç hastalıkları-onkoloji doçenti oldu, 2010 yılında ise profesörlüğe yükseltildi. Ege Üniversitesi Tülay Aktaş Onkoloji Hastanesi'nde görev yapmaktadır. Halen Tıbbi Onkoloji Bilim Dalı Başkanlığı görevini yürütmektedir.

Bilimsel Yayınları

• Ruchan Uslu, Ulus A. Sanli, Canfeza Sezgin, Bulent Karabulut, Serdar B. Omay, Erdem Goker. Arsenic trioxide-mediated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clinical Cancer Research, Dec; 6: 4958-4964, 2000.
• Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Guray Saydam, Serdar Bedii Omay, Erdem Goker. Which dosing scheme is suitable for the taxanes? An in vitro model. Archives of Pharmacal Research Aug; 25 (4): 550-5, 2002.
• Safak Yuksel, Guray Saydam, Ruchan Uslu, Ulus Ali Sanli, Ender Terzioglu, Filiz Buyukececi, Serdar Bedii Omay. Arsenic trioxide and methylprednisolone use different signal transduction pathways in leukemic differentiation. Leukemia Research, Apr; 26(4): 391-398, 2002.
• Burak Z, Moretti JL, Ersoy O, Sanli U, Kantar M, Tamgac F, Basdemir G. 99mTc-MIBI imaging as a predictor of therapy response in osteosarcoma compared with multidrug resistance-associated protein and P-glycoprotein expression. J Nucl Med. 2003 Sep;44(9):1394-401.
• Ulus Ali Sanli, Ruchan Uslu, Bulent Karabulut, Canfeza Sezgin, Nur Selvi, Hakan H. Aydın, Guray Saydam, Erdem Goker, Serdar Bedii Omay. Alterations in the activity and expression of serine/threonine protein phosphatases during all trans retinoic acid-induced apoptosis in breast cancer cells. Oncology Reports, Nov-Dec; 10(6): 2083-8, 2003.
• Gülperi Öktem, Bulent Karabulut, Nur Selvi, Canfeza Sezgin, Ulus Ali Sanli, Ruchan Uslu, Mine Ertem Yurtseven, Serdar Bedii Omay. Differential effects of doxorubicin and docetaxel on nitric oxide production and inducible nitric oxide synthase expression in MCF-7 human breast cancer cells. Oncology Research, 14: 381-386, 2004.
• Erdem Goker, Ulus Ali Sanli, Yildiray Yüzer, Ruchan Uslu, Bulent Karabulut, Ahmet Memis, Ahmet Coker, Ali Mentes. Bioembolisation for Unresectable Hepatocellular Carcinoma: Preliminary Results of a Translational Research Study. Journal of Experimental & Clinical Cancer Research, 23: 403-409, 2004. (7,14 puan)
• Karasulu HY, Karabulut B, Kantarci G, Ozgüney I, Sezgin C, Sanli UA, Göker E. Preparation of arsenic trioxide-loaded microemulsion and its enhanced cytotoxicity on MCF-7 breast carcinoma cell line. Drug Deliv. 2004 Nov-Dec;11(6):345-50.
• Ruchan Uslu, Ulus Ali Sanli, Yilmaz Dikmen, Bulent Karabulut, Aydin Ozsaran, Canfeza Sezgin, Gamze G. Muezzinoglu, Serdar B Omay, Erdem Goker. Predictive value of serum interleukin-8 levels in ovarian cancer patients treated with paclitaxel-containing regimens. International Journal of Gynecologic Cancer, 15: 240245, 2005.
• Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Ulus Ali Sanli, Gamze Goksel, Osman Zekioglu, Necmettin Ozdemir, Erdem Goker. Potential predictive factors for response to weekly paclitaxel treatment in patients with metastatic breast cancer. Journal of Chemotherapy, Feb; 17(1): 111-117, 2005.
• Bulent Karabulut, Canfeza Sezgin, Cosan M. Terek, Ruchan Uslu, Ulus Ali Sanli, Levent Akman, Aydin Özsaran, Yilmaz Dikmen, Erdem Göker. Topotecan in platinum-resistant epithelial ovarian cancer. Chemotherapy, Oct; 51(6): 347-51. Epub 2005 Oct 14, 2005.
• Canfeza Sezgin, Bulent Karabulut, Ruchan Uslu, Ulus Ali Sanli, Gamze Goksel, Yildiray Yüzer, Erdem Goker. Gemcitabine treatment in patients with inoperable locally advanced/metastatic pancreatic cancer and prognostic factors. Scandinavian Journal of Gastroenterology, Dec; 40(12): 1486-92, 2005.
• Terek, MC; Karabulut, B; Selvi, N; Akman, L; Karasulu, Y; Ozguney, I; Sanli, AU; Uslu, R; Ozsaran, A. Arsenic trioxide-loaded, microemulsion-enhanced cytotoxicity on MDAH 2774 ovarian carcinoma cell line. International Journal of Gynecological Cancer, Mar-Apr; 16(2): 532-537, 2006.
• Sanli UA, Karabulut B, Uslu R, Korkut M, Goker E. Single-agent irinotecan for recurrent/metastatic colorectal cancer: a retrospective analysis. Medicinal Principles and Practice, 15(4): 288-92, 2006.
• N. Askar, T. Cırpan, E. Toprak, B. Karabulut, N. Selvı, M.C. Terek, R. Uslu, U.A. Sanlı & E. Goker. Arsenic trioxide exposure to ovarian carcinoma cells leads to decreased level of topoisomerase II and cytotoxicity. International Journal of Gynecological Cancer, Jul-Aug; 16(4): 1552-6, 2006.
• Kucukzeybek Y, Gorumlu G, Karaca B, Erten C, Cengiz E, Kemal Gul M, Karabulut B, Uslu R, Sanli UA, Goker E. Docetaxel and platinum combination chemotherapy in locally advanced or metastatic head and neck cancer. Journal of B.U.ON Apr-Jun; 13(2): 199-203, 2008. (5 puan)
• Doganavsargil B, Argin M, Kececi B, Sezak M, Sanli UA, Oztop F. Secondary osteosarcoma arising in fibrous dysplasia, case report. Arch Orthop Trauma Surg. 2009 Apr;129(4):439-44. Epub 2008 Jun 17.
• Işikgoz Taşbakan M, Görümlü G, Pullukçu H, Sanli UA, Sipahi OR, Karabulut B, Tünger A. [A rare cause of catheter-related bacteremia: Rhizobium radiobacter] Mikrobiyol Bul. 2008 Apr;42(2):349-52.
• Kucukzeybek Y, Gul MK, Cengiz E, Erten C, Karaca B, Gorumlu G, Atmaca H, Uzunoglu S, Karabulut B, Sanli UA and Uslu R. Enhancement of Docetaxel-Induced Cytotoxicity and Apoptosis by All-Trans Retinoic Acid (ATRA) Through Downregulation of Survivin (Birc5), Mcl-1 and Ltbeta-R in Hormone- and Drug Resistant Prostate Cancer Cell Line, DU145. Journal of Experimental& Clinical Cancer Research, Sep 12; 27(1): 37, 2008.
• Saydam BK, Goksel G, Korkmaz E, Zekioglu O, Kapkac M, Sanli UA, Uslu R, Sezgin C. Comparison of inflammatory breast cancer and noninflammatory breast cancer in Western Turkey. Medicinal Principles and Practice, 17(6): 475-80, 2008.
• Gorumlu G, Kucukzeybek Y, Kemal Gul M, Karaca B, Terek M. Cosan, Karabulut B, Sanli UA, Akman L, Ozsaran A, Dikmen Y, Uslu R. Pegylated liposomal doxorubucin in heavily pretreated epithelial ovarian cancer patients. Journal of B.U.ON, Jul-Sep; 13(3): 349-352, 2008.
• Karaca B, Kucukzeybek Y, Gorumlu G, Erten C, Gul MK, Cengiz E, Atmaca H, Uzunoglu S, Sanli UA, Karabulut B, Uslu R. Profiling of angiogenic cytokines produced by hormone- and drug-refractory prostate cancer cell lines, PC-3 and DU-145 before and after treatment with gossypol. European Cytokine Network, Dec; 19 (4): 176-84, 2008.
• Karabulut B, Erten C, Gul MK, Cengiz E, Karaca B, Kucukzeybek Y, Gorumlu G, Atmaca H, Uzunoglu S, Sanli UA, Baran Y, Uslu R. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biology International, Feb; 33(2): 239-46, Epub 2008 Dec 11, 2009.
• Cigdem Erten, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Ercument Cengiz, Mustafa K. Gul, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli and Ruchan Uslu. Regulation of growth factors in hormone and drug-resistant prostate cancer cells by synergistic combination of docetaxel and octreotide. British Journal of Urology International, Jul; 104(1): 107-14, Epub 2009 Feb 3, 2009.
• Ercument Cengiz, Burcak Karaca, Yuksel Kucukzeybek, Gurbuz Gorumlu, Mustafa K. Gul, Cigdem Erten, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan. Overcoming drug resistance in hormone-and drug refractory prostate cancer cell line, PC-3 by a synergistic combination of docetaxel and gossypol. Molecular Biology Reports, Mar 14. [Epub ahead of print], 2009.
• Makay O, Gurcu B, Sanli UA, Zekioglu O, Oktay A, Goker E, Kapkac M. Complete response after chemotherapy in metastatic involvement of the orbita in breast cancer. Breast J. 2009 Jul-Aug;15(4):418-9. Epub 2009.
• Degirmenci M, Karaca B, Gorumlu G, Durusoy R, Demir Piskin G, Bozkurt MT, Cirak Y, Tunali D, Karabulut B, Sanli UA, Uslu R. Efficacy and safety of bevacizumab plus capecitabine and irinotecan regimen for metastatic colorectal cancer. Medical Oncology Jun 13. [Epub ahead of print], 2009.
• Sanli UA, Gorumlu G, Erten C, Gul MK, Cengiz E, Kucukzeybek Y, Karaca B, Atmaca H, Uzunoglu S, Karabulut B, Uslu R. Targeting apoptosis in the hormone- and drug-resistant prostate cancer cell line, DU-145, by gossypol/zoledronic acid combination. Cell Biology International Aug 27. [Epub ahead of print], 2009.
• Atmaca H, Gorumlu G, Karaca B, Degirmenci M, Tunali D, Cırak Y, Purcu DU, Uzunoglu S, Karabulut B, Sanli UA, Uslu R. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. European Cytokine Network, 2009.
• Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus A. Sanli, Ruchan Uslu. Enhancement of taxane-induced cytotoxicity and apoptosis by gossypol in human breast cancer cell line, MCF-7. Journal of B.U.ON, 2009
• Ozlem Akagunduz, Burcak Karaca, Harika Atmaca, Selim Uzunoglu, Bulent Karabulut, Ulus Ali Sanli, Ayfer Haydaroglu, Ruchan Uslu. Radiosensitization of Hormone-Refractory Prostate Cancer Cells by Gossypol Treatment. Journal of B.U.ON, 2009 (yayın için kabul edildi).
• Kucukzeybek Y, Gorumlu G, Cengiz E, Karabulut B, Sezgin C, Atmaca H, Sanli UA, Uzunoglu S, Uslu R. Apoptosis-mediated cytotoxic effects of ibandronic acid on hormone- and drug-refractory prostate cancer cells and human breast cancer cells. J Int Med Res. 2010 Sep-Oct;38(5):1663-72.
• Sezgin C, Gokmen E, Kapkac M, Zekioglu O, Esassolak M, Karabulut B, Sanli UA, Uslu R. p53 protein accumulation and presence of visceral metastasis are independent prognostic factors for survival in patients with metastatic inflammatory breast carcinoma. Med Princ Pract. 2011;20(2):159-64.
• . Karaca B, Atmaca H, Bozkurt E, Kisim A, Uzunoglu S, Karabulut B, Sezgin C, Sanli UA, Uslu R. Combination of AT-101/cisplatin overcomes chemoresistance by inducing apoptosis and modulating epigenetics in human ovarian cancer cells.. Mol Biol Rep. 2012 Dec 27. [Epub ahead of print]
• . Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Ali Sanli U, Uslu R. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer. J Oncol Pharm Pract. 2014 Sep 17. pii: 1078155214551315. [Epub ahead of print].
• Varol U, Degirmenci M, Karaca B, Atmaca H, Kisim A, Uzunoglu S, Sezgin C, Sanli UA, Uslu R. Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines. Tumour Biol. 2015 Feb;36(2):779-86. doi: 10.1007/s13277-014-2682-6
• Arican A1, Bozkurt T, Bozcuk H, Demirkan B, Buyukberber S, Alkis N, Sanli UA, Camci C, Yildiz M, Yucel I, Uygun K, Aslay I, Demiray M, Bese NS, Isikdogan A, Bahat Z, Gemici C, Ozdemir F, Ozdener F, Pekin B. A cross-sectional survey of the diagnosis and management of bone metastasis in breast cancer patients in Turkey. Support Care Cancer. 2014 Oct;22(10):2629-34. doi: 10.1007/s00520-014-2253-9. Epub 2014 Apr 22.
• Karaca B, Degirmenci M, Ozveren A, Atmaca H, Bozkurt E, Karabulut B, Sanli UA, Uslu R. Docetaxel in combination with octreotide shows synergistic apoptotic effect by increasing SSTR2 and SSTR5 expression levels in prostate and breast cancer cell lines. Cancer Chemother Pharmacol. 2015 Jun;75(6):1273-80. doi: 10.1007/s00280-015-2756-1. Epub 2015 Apr 30.
• Surmeli Z, Gursoy P, Erdogan AP, Bozkurt E, Atmaca H, Uzunoglu S, Sezgin C, Şanlı UA, Uslu R, Karaca B. Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway. Tumour Biol. 2015 Oct 13. [Epub ahead of print].
• Surmeli ZG, Varol U, Cakar B, Degirmenci M, Arslan C, Piskin GD, Zengel B, Karaca B, Sanli UA, Uslu R. Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncol Lett. 2015 Oct;10(4):2598-2602. Epub 2015 Jul 29.
• Bicakli DH, Varol U, Degirmenci M, Tunali D, Cakar B, Durusoy R, Karaca B, Sanli UA, Uslu R. Reply To the Editor, Re: Bicakli et al. Adjuvant chemotherapy may contribute to an increased risk for metabolic syndrome in patients with breast cancer.. J Oncol Pharm Pract. 2015 Aug;21(4):318-9. doi: 10.1177/1078155215585051. Epub 2015 May 15.
• The retrospective analysis of patients with uterine sarcomas: A single-center experience. Terek MC, Akman L, Hursitoglu BS, Sanli UA, Ozsaran Z, Tekindal MA, Dikmen Y, Zekioglu O, Ozsaran AA. J Cancer Res Ther. 2016 Jan-Mar;12(1):309-13. doi: 10.4103/0973-1482.148698.
• Ovarian sertoli-leydig cell tumors: A multicenter long-term clinicopathological analysis of 27 patients. Akman L, Ertas IE, Gokcu M, Terek MC, Sanci M, Sanli UA, Zekioglu O, Ozsaran AA. J Cancer Res Ther. 2016 Jan-Mar;12(1):290-4. doi: 10.4103/0973-1482.158037
• Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway. Surmeli Z, Gursoy P, Erdogan AP, Bozkurt E, Atmaca H, Uzunoglu S, Sezgin C, Şanlı UA, Uslu R, Karaca B. Tumour Biol. 2016 Mar;37(3):3665-73. doi: 10.1007/s13277-015-3265-x.